NCT06688292 - The Safety and Effectiveness of Taneasy and Actein in COPD Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

COPD (Chronic Obstructive Pulmonary Disease)

Interventions

DRUG

Taneasy 600mg granules

Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis.

DRUG

Actein effervescent 600mg

Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, pulmonary emphysema, mucoviscidosis and bronchiectasis.

Trial Locations (1)

Unknown

Taichung Veterans General Hospital, Taichung